GlassScriptPhysician profile
Timothy R Lavender
NPI 1669426003
$10,232.10
in general payments reported to CMS, 2019-2025
23 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $941 · 2021: $1,641 · 2022: $1,656 · 2023: $1,825 · 2024: $1,569 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,838 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,837.58 |
| Education | $270.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,655.71 | 2019-2025 | |
| Janssen Biotech, INC. | $1,611.89 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,467.93 | 2019-2025 | Ilumya, Blu-U, Levulan Kerastick |
| Ucb, INC. | $1,186.58 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $1,087.52 | 2020-2025 | |
| Dermavant Sciences, INC. | $403.74 | 2022-2024 | Vtama |
| Amgen INC. | $329.50 | 2019-2023 | Otezla |
| Leo Pharma INC. | $267.67 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $211.03 | 2020-2023 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $178.99 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $163.69 | 2019-2022 | |
| Biofrontera INC. | $156.38 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $86.92 | 2019-2021 | |
| Lilly USA, LLC | $83.67 | 2019-2020 | |
| Genentech USA, INC. | $65.18 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $61.69 | 2019-2022 | |
| Galderma Laboratories, L.P. | $56.90 | 2019-2024 | |
| Organon LLC | $47.57 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $37.65 | 2025 | Zoryve |
| Celgene Corporation | $22.01 | 2019 | |
| Smith+Nephew, INC. | $21.83 | 2025 | Collagenase Santyl |
| Dusa Pharmaceuticals, INC. | $16.97 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lavender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.